The Same Virus That Kills Bacteria Can Also Arm Them With Resistance
Phage therapy's promise as an antibiotic alternative comes with an overlooked risk: the same viruses that destroy bacteria can spread resistance genes between species.
Phage therapy, offered at institutions like Georgia's Eliava Institute, offers hope against antibiotic-resistant infections by using viruses that naturally prey on bacteria. However, these bacteriophages can inadvertently shuttle resistance genes between bacteria during infection, spreading antibiotic defenses horizontally across species. This risk is managed through carefully designed phage cocktails, but the underlying biology remains unchanged. The takeaway is that phage therapy's promise and its peril are inseparable—they emerge from the same viral mechanism.
In Tbilisi, Georgia, a clinic called the Eliava Institute has spent decades doing something most hospitals won't attempt: injecting viruses into patients to kill bacteria. The viruses are bacteriophages—natural bacterial predators that can wipe out antibiotic-resistant infections that would otherwise be untreatable. For patients who have cycled through multiple antibiotic courses with no relief, phage therapy can look like a lifeline. Here is the complication that standard explanations tend to skip. Every phage particle that enters a patient carries a history. When a phage infects a bacterium and replicates, it sometimes packages fragments of the previous host's genetic material alongside its own DNA. That cargo can include resistance genes—instructions the bacterium used to defend itself against antibiotics. When that phage then infects a new bacterium, it can deposit those genes into the new host, arming bacteria that have never encountered antibiotics with the tools to resist them. This is not a design flaw in phage therapy. It is a feature of how bacteriophages operate in nature. The same mechanism that makes phages effective bacterial killers is the same mechanism that makes them potential resistance spreaders. The weapon and the vulnerability share the same machinery. In practice, phage therapists manage this risk by using carefully curated phage cocktails—mixtures selected to minimize the chance that any single phage will shuttle resistance genes between clinically relevant bacteria. The Eliava Institute has refined this approach over decades. But even in controlled settings, the underlying biology does not change: phages do not distinguish between delivering therapeutic payloads and delivering resistance genes. They deliver genetic material, period. This is why phage therapy requires a different kind of vigilance than conventional antibiotics. With antibiotics, the failure mode is typically that bacteria evolve resistance through slow, vertical inheritance—mutations passed from parent to daughter over generations. With phage therapy, resistance can spread horizontally, across species boundaries, between bacteria that never physically meet, carried by viral particles that are doing exactly what they were designed to do. The takeaway is not that phage therapy should be abandoned. It remains one of the most promising alternatives for infections that antibiotics can no longer touch. The takeaway is that phage therapy's promise and its risk are not separate concerns—they are the same biological process viewed from different angles.